Krystal Biotech (KRYS) Set to Announce Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) will release its earnings data before the market opens on Monday, May 6th. Analysts expect Krystal Biotech to post earnings of $0.28 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to analysts’ expectations of $27.43 million. During the same quarter last year, the company earned ($1.25) EPS. On average, analysts expect Krystal Biotech to post $2 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $161.10 on Friday. The company has a market cap of $4.59 billion, a P/E ratio of 2,014.00 and a beta of 0.91. Krystal Biotech has a one year low of $82.09 and a one year high of $189.97. The firm has a fifty day moving average of $169.04 and a two-hundred day moving average of $133.14.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,087 shares of company stock worth $6,210,591. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

KRYS has been the subject of several recent analyst reports. Guggenheim raised their price target on Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. William Blair reaffirmed an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a report on Monday, April 22nd. Citigroup raised their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $171.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).